IL17A and deep vein thrombosis: Recombinant IL-17A administration exacerbates the development of DVT; this effect can be nullified by blocking IL-17, a step mediated by enhanced platelet activation and aggregation, neutrophil infiltration, and EC activation in a mouse experiment [76].